menu
    • menu
    [{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Ricerche Announces the Latest Findings of Its Vaborem\u2122 and Quofenix\u2122 Clinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Delafloxacin","moa":"Topoisomerse 4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Not Applicable"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Delafloxacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Melinta Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Melinta Therapeutics \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$141.9 million","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Delafloxacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Melinta Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Melinta Therapeutics \/ BARDA"}]

    Find Clinical Drug Pipeline Developments & Deals for Delafloxacin

    Menu

    Delafloxacin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Melinta Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Melinta Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Delafloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : BARDA

                            Deal Size : $141.9 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients...

                            Details : The partnership aims to advance two antibiotics currently FDA-approved for adults, Baxdela (delafloxacin) and Vabomere (meropenem and vaborbactam), for use in pediatrics and also for the development of Baxdela against biothreat pathogens for both adults ...

                            Brand Name : Baxdela

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 10, 2023

                            Lead Product(s) : Delafloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : BARDA

                            Deal Size : $141.9 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Melinta Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Melinta Therapeutics

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Delafloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Xediton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective ...

                            Details : Under the terms of the agreement, Xediton is responsible for the registration and commercialization of BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective produ...

                            Brand Name : Baxdela

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 15, 2023

                            Lead Product(s) : Delafloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Xediton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Menarini

                            Italy arrow
                            AAPS 2024
                            Not Confirmed

                            Menarini

                            Italy arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Delafloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Menarini Ricerche Announces the Latest Findings of Its Vaborem™ and Quofenix™ Clinical Studies

                            Details : Menarini Ricerche has published four abstracts presenting the latest findings related to its meropenem/vaborbactam (Vaborem™) and delafloxacin (Quofenix™) clinical studies, confirming Menarini’s commitment to fighting life-threatening bacterial inf...

                            Brand Name : Quofenix

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 09, 2020

                            Lead Product(s) : Delafloxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth